Hospital Universitari de Bellvitge Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00396721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain. | Daniel Podzamczer | Gynaecology Unit, Bellvitge University Hospital (HUB), L'Hospitalet del Llobregat, Spain. | Hospital Universitari de Bellvitge - Angiology and Vascular Surgery Department | Hospital Universitario de Bellvitge | Isabel Lopez Zamora | José María Piulats Rodríguez | Josep Maria Ramon Torrell, PhD | Josep m Cruzado | Josep M Cruzado | M. Carmen Cabellos Minguez | Miguel Santín | Núria Sabé Fernàndez | Sebastian Videla | Unidad de Trasplante Renal - Hospital Universitari de Bellvitge